Importantly, the beneficial contribution of the MHCII-CD4 axis to tumor control was also revealed by our analysis of TCGA-GBM datasets, which showed that GBM patients expressing higher MHCII (based on combined log-averaging of HLA-DRA, HLA-DQA1, and HLA-DQB1 transcript levels) had better survival outcomes than their lower expression counterparts in the CD4hi cohort (Fig. 1h). Here, CD4 is linked to glioblastoma.